The nanotechnology research-based biopharmaceutical company, VAV Life Sciences, is ramping up the production of crucial lipid ingredients essential for manufacturing liposomal amphotericin B, the drug used for treating mucormycosis also known as the black fungus infection.
The company is taking immediate steps to increase the production of the lipids within the next three months to keep up with the rising demand of the compound from the pharmaceutical industry to manufacture the medication,
The company plans to expand its present capacity of 21 kg per month to 65 kg per month, by August 2021. This would help pharmaceutical companies produce about 3 lakh vials of liposomal amphotericin B. VAV will also further increase its capacity to 130 kg per month by December, which would add approximately 6 lakh vials of the medication to the pharmaceutical supply chain, by the end of 2021.
Speaking of the company’s plans to expand production, Arun Kedia, Managing Director, VAV Life Sciences said, “The unprecedented demand of Liposomal Amphotericin B has put tremendous pressure on the supply chain for raw materials. Since our company plays such a crucial role in the supply chain, we are working round the clock to keep up with the demand from pharmaceutical companies for these crucial ingredients that will help them manufacture this medication in sufficient quantities.”
The company will manufacture the lipid ingredients at its EU cGMP certified facility under its subsidiary company, VAV Lipids, based at Ratnagiri in Maharashtra.VAV Life Sciences is the only Indian company that indigenously produces the highly purified synthetic phospholipids needed for producing Liposomal Amphotericin B, said the company. Apart from this it also plays a vital role in the global Covid-19 vaccine supply chain by manufacturing other specialised lipids that are used in mRNA-based Covid-19 vaccines.